What is ipamorelin?

A selective growth hormone secretagogue

Ipamorelin is a five-amino-acid peptide that pushes the pituitary gland to release its own growth hormone. Novo Nordisk developed it in the 1990s, and the defining paper, published in the European Journal of Endocrinology in 1998, described it as the first selectivegrowth hormone secretagogue. The word selective is doing real work there. Earlier compounds in the same class, growth hormone-releasing peptides like GHRP-6, triggered a GH pulse but also raised cortisol, ACTH, and prolactin along with it. Ipamorelin's researchers found it released GH at doses up to 200 times higher than needed without moving those other hormones. That selectivity is the actual scientific contribution behind the peptide, and it is real.

Mechanistically, ipamorelin binds the ghrelin receptor, GHS-R1a, the same receptor that the hunger hormone ghrelin activates. That is different from how tesamorelin, the one FDA-approved peptide in this category, works. Tesamorelin mimics growth-hormone-releasing hormone (GHRH) and tells the pituitary a GH pulse is due. Ipamorelin instead amplifies how big that pulse is. The two mechanisms are complementary on paper, which is the entire rationale for stacking a GHRH analog with a ghrelin-receptor agonist.

The human data that actually exists

Ipamorelin has more human trial history behind it than most peptides sold in the current market, including the ones this site has covered from the July 2026 FDA compounding hearing. Small pharmacokinetic studies in healthy male volunteers, published in the same era as the discovery paper, mapped out its behavior in the body: a roughly two-hour half-life, a single GH pulse peaking about 40 minutes after dosing, and a dose-proportional response across a range of infusion rates.

That one efficacy trial matters. Ipamorelin's developer at the time, Helsinn Therapeutics, ran a randomized, placebo-controlled Phase 2 study in 114 patients recovering from bowel resection surgery, testing whether the drug sped up the return of normal gut motility, a common and costly complication called postoperative ileus. The safety signal was good: patients on ipamorelin reported fewer adverse events than the placebo group. But the trial missed its primary endpoint, time to first bowel movement, and Helsinn discontinued the program afterward. That is the full extent of ipamorelin's controlled human efficacy data. It exists. It also did not work for the thing it was actually tested on.

What has never been tested

Nobody has published a human trial testing ipamorelin for the reasons it is actually sold today: muscle preservation, fat loss, recovery, sleep, or general anti-aging. Every claim about those uses traces back to the peptide's mechanism, that more growth hormone pulses should plausibly help with body composition, not to a completed study measuring whether it does. That is a meaningfully different evidence position than tesamorelin, which has a published, positive Phase 3 program behind its approved indication, even though that indication is narrower than most people assume.

Ipamorelin versus CJC-1295

The two peptides get sold as a pair because they act on different parts of the same pathway. CJC-1295 is a long-acting GHRH analog, it tells the pituitary a GH release is due. Ipamorelin is a ghrelin-receptor agonist, it makes that release larger once it happens. Combining a GHRH signal with a ghrelin-receptor amplifier is a coherent mechanistic idea, and it is the same logic behind approved combination therapies in other areas of endocrinology.

What does not exist is a published human trial of the ipamorelin-CJC-1295 combination itself. Each peptide individually has thin data, as described above. Stacked together, the evidence is entirely inferential: two mechanisms that should complement each other, with no study confirming that they actually do, or at what dose, or with what side-effect profile when combined.

The 2026 legal status: already reviewed, already rejected

This site has covered the FDA's July 2026 hearing on BPC-157, TB-500, and five other peptides in detail, where an advisory panel voted 8-6 to recommend those substances for compounding despite FDA staff's own recommendation against them. Ipamorelin's regulatory story ran on a different, quieter track, and it ended the opposite way.

In September 2024, the nomination that had placed ipamorelin acetate on the FDA's Category 2 list, the tier reserved for substances the agency considers a significant safety risk, was withdrawn. That took it off the danger list, but it did not put it on any approved list. The FDA's Pharmacy Compounding Advisory Committee then formally reviewed ipamorelin, alongside ibutamoren, L-theanine, and kisspeptin-10, at its October 29, 2024 meeting, weighing whether to add it to the 503A bulks list, the list that would let licensed compounding pharmacies legally prepare it from bulk material. The panel voted against inclusion, citing insufficient human safety data to support routine compounding.

No further rulemaking has moved ipamorelin onto that list since. Practically, that means ipamorelin is not flagged as a known safety hazard, but it also never cleared the review that would make compounding it through a licensed 503A pharmacy clearly legal. The wide market selling it through telehealth peptide clinics and research-chemical vendors is operating in that gap, not through an FDA-cleared pathway the way a properly licensed compounding pharmacy would for an approved drug.

Dosing, side effects, and the gap between trial and practice

In the postoperative ileus trial, ipamorelin's side-effect profile was mild: injection-site reactions, headache, flushing, and occasional lightheadedness, at rates no higher than placebo. Because it works through the ghrelin receptor, the same one that drives hunger signaling, it can also increase appetite, which is a notable side effect for anyone using it alongside a GLP-1.

That safety data covers short courses of closely monitored, in-hospital dosing after surgery. It does not cover how most buyers actually use it: nightly subcutaneous injections, commonly cited at 200 to 300 micrograms, self-administered for months or years at a time, often alongside CJC-1295. No FDA-sanctioned dose exists for that pattern of use, because no trial has studied it. The gap between what was tested and what is actually practiced is the central fact about this peptide.

Where it fits, honestly

Ipamorelin is not a fraud peptide with zero science behind it. The receptor selectivity that made it notable in 1998 is real, and its pharmacokinetics in humans are better characterized than most compounds sold alongside it. But the specific use it is marketed for now, body composition and muscle preservation for people running a peptide stack or coming off a GLP-1 and worried about muscle loss, has never been tested in a published trial, and its one completed efficacy trial failed. An FDA panel already looked at the safety case and said it was not enough. Anyone weighing whether to add it to a stack is not weighing thin evidence against strong evidence. They are weighing plausible mechanism against an actual, recorded no.